The early RAINIER data showed a 79% CR/CRi rate in evaluable frontline TP53-mutated AML patients, comparing favorably with a published 41% composite remission benchmark for venetoclax plus azacitidine.
Key Investor Takeaways
- Aptevo Therapeutics Inc. (NASDAQ:APVO) reported a 93% clinical benefit rate among 14 evaluable TP53-mutated AML patients receiving mipletamig with venetoclax and azacitidine.
- Eleven of the 14 patients achieved complete remission or complete remission with incomplete hematologic recovery, producing a 79% CR/CRi rate, including nine complete remissions.
- The company highlighted a published 41% composite remission rate for venetoclax plus azacitidine in treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML as a benchmark.
- The results come from a small patient population and the RAINIER program remains in Phase 1b/2 development, making further clinical validation important.
- Dose optimization is expected to finish by year-end, with regulatory interaction planned for the first half of 2027 to determine the program’s next steps.
Why APVO Stock Is in Focus
Aptevo has reported encouraging response data for its mipletamig triplet in TP53-mutated frontline AML, a patient subgroup the company describes as historically difficult to treat.
Among 14 evaluable TP53-mutated patients receiving mipletamig alongside venetoclax and azacitidine, 13 experienced clinical benefit, representing a 93% rate. Clinical benefit included complete remission, CR with incomplete hematologic recovery, partial response and morphologic leukemia-free state.
More specifically, 11 patients, or 79%, achieved CR or CRi, including nine complete remissions.
Aptevo compared that result with a published 41% composite remission rate for venetoclax plus azacitidine in treatment-naïve patients with poor-risk cytogenetics and TP53-mutated AML. The benchmark comes from a 2022 Clinical Cancer Research publication and is not a randomized head-to-head comparison within RAINIER.
Why This Matters for Investors
The data potentially strengthen the clinical case for mipletamig in a particularly challenging AML population.
TP53 mutations are associated with resistance to treatment and historically poorer outcomes, according to the company. Demonstrating a high remission rate in this subgroup therefore provides an important early signal as Aptevo evaluates whether adding mipletamig can improve outcomes over the venetoclax-azacitidine backbone.
The 79% CR/CRi result is notable relative to the 41% published benchmark cited by Aptevo. However, investors should interpret that comparison cautiously. Only 14 TP53-mutated patients were evaluable, including two from the previously completed dose-expansion trial, and the comparison involves separate studies rather than randomized treatment groups.
That makes durability, consistency across additional patients and subsequent trial results important to determining the significance of the initial response rates.
The data also arrive ahead of a defined regulatory milestone. Aptevo expects the current dose-optimization phase of RAINIER to finish by year-end and plans regulatory interaction during the first half of 2027. That discussion could provide greater clarity on the development pathway for mipletamig.
What to Watch Next
Completion of RAINIER dose optimization by the end of 2026 is the next major clinical milestone, with investors likely to focus on whether response rates remain consistent as the dataset develops.
Attention will then shift toward Aptevo’s planned first-half 2027 regulatory interaction and what it indicates about subsequent clinical development.
Additional data on response durability and outcomes in TP53-mutated patients could also help establish whether the encouraging early remission results translate into a more durable treatment benefit.